Stomach Pain News and Research

RSS

Insurers under fire for denials of care, inadequate coverage

When people talk about revamping the health care system, among the often-mentioned reasons for change are unfair denials of care by insurance companies and medical debt, both of which are in the news today.

24 Nov 2009

Illegal residents' view on healthcare status

The dissertation focuses on how individual non-citizens residing illegally in the country perceive their health status, what wishes they have regarding healthcare, and whether these wishes are fulfilled. The individual perspective is used instead of the more common concepts of health and healthcare needs, which are based more on the care-giver perspective.

22 Oct 2009

National study results change common method of treating asthma

A nationwide study of adults with asthma reveals no benefit for treatment for silent acid reflux, which long has been thought to be the culprit for some severe asthma symptoms such as coughing, wheezing and breathlessness.

8 Apr 2009

Experts say exotic pet pose health risks to young children

Experts say exotic pets such as reptiles and monkeys should be discouraged in homes with small children or people with immune system problems, as they pose a health risk.

7 Oct 2008

21 new genes found for Crohn's disease

A consortium of researchers from the United States, Canada, and Europe has identified 21 new genes for Crohn's disease, a chronic disease of the large and small intestines.

21 Jul 2008

Human vaccine for Ebola in the pipeline

The deadly Ebola virus is in the news again but this time there is the promise of a vaccine for the deadly disease.

1 Apr 2008

Ebola virus vaccines for humans

One of the world's deadliest diseases, caused by the Ebola virus, may finally be preventable thanks to US and Canadian researchers, who have successfully tested several Ebola vaccines in primates and are now looking to adapt them for human use.

31 Mar 2008

As depression symptoms improve with antidepressants, hopelessness can linger

People taking medication for depression typically see a lot of improvements in their symptoms during the first few months, but lagging behind other areas is a sense of hopefulness, according to new research from the University of Michigan Health System.

18 Feb 2008

Takeda submits NDA for Alogliptin (SYR-322) in the U.S.

Takeda Pharmaceutical Company Limited (Takeda) has announced that Takeda Global Research & Development Center, Inc. submitted a New Drug Application (NDA) to the United States Food and Drug Administration (FDA) for alogliptin (development code: SYR-322), a highly selective dipeptidyl peptidase-4 (DPP-4) inhibitor under investigation for the treatment of type 2 diabetes.

7 Jan 2008

ACTOS associated with reduced risk of heart attack and stroke in patients with type 2 diabetes

Results presented at the 43rd Annual Meeting of the European Association for the Study of Diabetes demonstrate the ability of ACTOS (pioglitazone HCl) to reduce the risk of ischemic cardiovascular disease in patients with type 2 diabetes.

20 Sep 2007

Have you ever experienced pain in your abdomen?

Of course, all of us have experienced a “belly ache” sometime in our lives, but how can you decide when abdominal pain is serious? While most stomach pain isn't serious, persistent or severe pain should not be ignored.

16 Aug 2007

Zinc lozenges are not effective in treating colds

Despite 20 years of research, the benefits of zinc lozenges as a therapy for the common cold have not been proven.

3 Aug 2007

Coated aspirin doesn't guarantee problem-free use

Some people take aspirin without ever having a problem with their stomach. Others develop low-grade stomach pain or get an ulcer.

31 Jul 2007

Takeda responds to FDA recommendation on Actos

Following a joint meeting today of the U.S. Food and Drug Administration (FDA) Endocrinologic and Metabolic Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee, Takeda Global Research & Development (TGRD) underscores its position that ACTOS(R) (pioglitazone HCl) offers a proven safety profile regarding the risk of cardiovascular disease.

30 Jul 2007

Bristol-Myers Squibb announces new results of Baraclude (entecavir) resistance monitoring program

Bristol-Myers Squibb Company has announced new results of the Baraclude (entecavir) resistance monitoring program, which found a continued low incidence of resistance in studies of nucleoside-naive chronic hepatitis B patients through four years of treatment.

16 Apr 2007